As I've said in the past, it's hard to argue with the premise from an investment standpoint.
I do find this interesting:
But the PBM industry's "Holy Grail" is generic drugs sold via mail order.
Their prices are lower than those charged for brand-name drugs. But generics are more profitable, and eliminating the retail pharmacy from the transaction places all of that profit into the PBM's pocket.
I think it proves my point. If the PBM makes the money, does the sponsor really save?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.